Study wrapper · #1080
Ability of Adults to Correctly Use Grey Market Peptide Semaglutide GLP-1 Receptor Agonists Acquired Without a Prescription.
Sedensky A, Nuzi K, Nolan L, et al. Public health reports. 2026.
DOI: 10.1177/00333549261464876PubMed: 42541373
Editor's note
This small usability study directly concerns semaglutide obtained through the grey market and the safety risks of untrained self-injection, which is squarely relevant to our readers. The sample of 20 is small and the design measures task performance rather than clinical outcomes, so it is best regarded as a cautionary signal. It reinforces the risks associated with unsupervised, non-prescription peptide use.
Plain-language abstract
In a small study of 20 adults, participants correctly completed only about 44% of the steps needed to safely self-administer grey-market semaglutide bought without a prescription. Errors could lead to incorrect dosing, needle sticks, or infections.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026